JHEP Reports最新文献

{"title":"Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake","authors":"Emil Deleuran Hansen ,&nbsp;Nikolaj Torp ,&nbsp;Stine Johansen ,&nbsp;Johanne Kragh Hansen ,&nbsp;Marianne Lerbæk Bergmann ,&nbsp;Camilla Dalby Hansen ,&nbsp;Sönke Detlefsen ,&nbsp;Peter Andersen ,&nbsp;Ida Villesen ,&nbsp;Katrine Bech ,&nbsp;Katrine Thorhauge ,&nbsp;Gitte Hedegaard Jensen ,&nbsp;Katrine Prier Lindvig ,&nbsp;Torben Hansen ,&nbsp;Emmanuel A. Tsochatzis ,&nbsp;Jonel Trebicka ,&nbsp;Maja Thiele ,&nbsp;Aleksander Krag ,&nbsp;Mads Israelsen ,&nbsp;the GALAXY and MicrobLiver consortia","doi":"10.1016/j.jhepr.2024.101200","DOIUrl":"10.1016/j.jhepr.2024.101200","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Quantifying alcohol intake is crucial for subclassifying participants with steatotic liver disease (SLD) and interpreting clinical trials of alcohol-related liver disease (ALD) and metabolic and alcohol-related liver disease (MetALD). However, the accuracy of self-reported alcohol intake is considered imprecise. We compared the diagnostic and prognostic utility of self-reported alcohol intake with blood-based biomarkers of alcohol intake: phosphatidylethanol (PEth) and carbohydrate-deficient transferrin (CDT).</div></div><div><h3>Methods</h3><div>We studied 192 participants from two randomized controlled trials on MetALD and ALD, all with current or former excessive alcohol intake (≥24/36 [♀/♂] grams daily for at least 1 year) and biopsy-proven liver disease. We assessed self-reported alcohol intake, PEth, and CDT at four time points. We collected follow-up data on hepatic decompensation and death manually through electronic medical records.</div></div><div><h3>Results</h3><div>Most participants were male (n = 161, 84%) with a mean age of 59 (SD 9) years and 73 participants reported 1-week abstinence before inclusion; the remaining reported a median alcohol intake of 43 g/day. Median PEth was 0.5 μmol/L (IQR: 0.0–1.3) and %CDT = 1.9 (IQR: 1.6–2.3). Of 32 patients reporting at least 6 months of abstinence; 27 (84%) was confirmed by PEth &lt;0.05 μmol/L. Self-reported alcohol intake correlated well with PEth (r = 0.617) and moderately with CDT (r = 0.316). Self-reported alcohol intake, PEth, and CDT all predicted hepatic decompensation and death. However, PEth showed the highest prediction, surpassing self-reported alcohol intake (Harrel’s C, PEth = 0.80 <em>vs.</em> self-reported = 0.68, <em>p</em> = 0.026).</div></div><div><h3>Conclusions</h3><div>Self-reported abstinence can be considered reliable in clinical trials. However, PEth is superior in predicting hepatic decompensation and death in patients with MetALD and ALD.</div></div><div><h3>Impact and implications</h3><div>An accurate quantification of alcohol intake is crucial in the clinical phenotyping of patients with steatotic liver disease and when designing clinical trials. This study found self-reported abstinence to be reliable but phosphatidylethanol was a more accurate prognostic biomarker of hepatic decompensation and death in a clinical trial setting. Findings may inform the design of future trials in patients with steatotic liver disease.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"7 1","pages":"Article 101200"},"PeriodicalIF":9.5,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Board page","authors":"","doi":"10.1016/S2589-5559(24)00207-6","DOIUrl":"10.1016/S2589-5559(24)00207-6","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 9","pages":"Article 101203"},"PeriodicalIF":9.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924002076/pdfft?md5=e4a27c989694a622d4c22d6a3640d55d&pid=1-s2.0-S2589555924002076-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142148334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright and information","authors":"","doi":"10.1016/S2589-5559(24)00210-6","DOIUrl":"10.1016/S2589-5559(24)00210-6","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 9","pages":"Article 101206"},"PeriodicalIF":9.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589555924002106/pdfft?md5=36611aac042aa5927b580993b9e51763&pid=1-s2.0-S2589555924002106-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142148336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting liver ablation volumes with real-time MRI thermometry","authors":"Osman Öcal ,&nbsp;Olaf Dietrich ,&nbsp;Sergio Lentini ,&nbsp;Pierre Bour ,&nbsp;Thibaut Faller ,&nbsp;Valery Ozenne ,&nbsp;Florian Maier ,&nbsp;Matthias Philipp Fabritius ,&nbsp;Daniel Puhr-Westerheide ,&nbsp;Vanessa F. Schmidt ,&nbsp;Elif Öcal ,&nbsp;Ricarda Seidensticker ,&nbsp;Moritz Wildgruber ,&nbsp;Jens Ricke ,&nbsp;Max Seidensticker","doi":"10.1016/j.jhepr.2024.101199","DOIUrl":"10.1016/j.jhepr.2024.101199","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>MRI guidance offers better lesion targeting for microwave ablation of liver lesions with higher soft-tissue contrast, as well as the possibility of real-time thermometry. This study aims to evaluate the correlation of real-time MR thermometry-predicted lesion volume with the ablation zone in postprocedural first-day images.</div></div><div><h3>Methods</h3><div>This single-center retrospective analysis evaluated prospectively included patients who underwent MRI-guided microwave ablation with real-time thermometry between December 2020 and July 2023. All procedures were performed under general anesthesia on a 1.5 T MRI scanner. Real-time thermometry data were acquired using multi-slice gradient-echo echoplanar imaging sequences, and thermal dose maps (CEM43 of 240 min as a threshold) were created. The volume of tissue exposed to a lethal thermal dose in MR thermometry (thermal dose) was compared with the ablation zone volume in portal phase T1w MRI on the postprocedural first day using the Pearson correlation test, and visual quantitative assessment by radiologists was performed to evaluate the similarity of shapes and volumes.</div></div><div><h3>Results</h3><div>Out of 30 patients with 33 lesions with thermometry images, six (18.1%) lesions were excluded because of artifacts limiting interpretation of thermal dose volume. Twenty-four patients with 27 lesions (20 male, age 63.1 ± 9.1 years) were evaluated for the volume correlation. The volume of thermal dose-predicted lesions and the postprocedural first-day ablation zones showed a strong correlation (R = 0.89, <em>p</em> &lt;0.001). Similarly, visual similarity of molecular resonance thermometry-predicted shape and the ablation zone shape was graded as perfect in 23 (85.1%) lesions.</div></div><div><h3>Conclusions</h3><div>Real-time thermal dose-predicted volumes show very good correlation with the ablation zone volumes in images obtained 1 day after the procedure, which could reduce the local recurrence rates with the possibility of re-ablating lesions within the same procedure.</div></div><div><h3>Impact and implications:</h3><div>Heat-based ablation is an established treatment for liver tumors; however, there is a considerable rate of incomplete treatment because of the lack of real-time visualization of the treated area during treatment. Our results show that MRI-guided ablation enables the visualization of the treatment area in real-time with high accuracy using a special technique of MR thermometry in patients with liver tumors.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 11","pages":"Article 101199"},"PeriodicalIF":9.5,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: “Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma”","authors":"Christiana Graf ,&nbsp;Christoph Sarrazin ,&nbsp;Julia Dietz","doi":"10.1016/j.jhepr.2024.101197","DOIUrl":"10.1016/j.jhepr.2024.101197","url":null,"abstract":"","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 12","pages":"Article 101197"},"PeriodicalIF":9.5,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142657124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hic-5 antisense oligonucleotide inhibits advanced hepatic fibrosis and steatosis in vivo","authors":"Masahito Noguchi ,&nbsp;Aya Miyauchi ,&nbsp;Yoshiaki Masaki ,&nbsp;Masashi Sakaki ,&nbsp;Xiao-Feng Lei ,&nbsp;Momoko Kobayashi-Tanabe ,&nbsp;Akira Miyazaki ,&nbsp;Takeshi Aoki ,&nbsp;Hitoshi Yoshida ,&nbsp;Kohji Seio ,&nbsp;Joo-ri Kim-Kaneyama","doi":"10.1016/j.jhepr.2024.101195","DOIUrl":"10.1016/j.jhepr.2024.101195","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Chronic liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), pose a significant global health burden. Progressive liver fibrosis can lead to severe outcomes; however, there is a lack of effective therapies targeting advanced fibrosis. Hydrogen peroxide-inducible clone-5 (Hic-5), an adaptor protein in focal adhesion, is critical for promoting liver fibrosis in hepatic stellate cells. This study investigated its clinical applicability by examining hepatic Hic-5 expression in human fibrotic tissues, exploring its association with MASH, and assessing the therapeutic potential of antisense oligonucleotides (ASOs) targeting Hic-5 in a MASH mouse model.</div></div><div><h3>Methods</h3><div>Hepatic Hic-5 expression in human fibrotic tissues underwent pathological image analysis and single-cell RNA sequencing. ASOs targeting Hic-5 were developed and tested using <em>in vitro</em> cell models. An <em>in vivo</em> MASH mouse model was used to evaluate the effects of anti-<em>Hic-5</em> ASOs on advanced fibrosis and steatosis.</div></div><div><h3>Results</h3><div>Hepatic Hic-5 expression increased with the progression of fibrosis, particularly in advanced stages. Single-cell RNA sequencing revealed Hic-5 expression primarily in hepatic stellate cells. In MASH-associated fibrosis, Hic-5 expression correlated with the expression of fibrotic genes. In the MASH mouse model, hepatic Hic-5 expression increased with disease progression. Anti-<em>Hic-5</em> ASOs effectively suppressed Hic-5 expression <em>in vitro</em> and attenuated advanced fibrosis and steatosis <em>in vivo</em>, indicating their therapeutic potential.</div></div><div><h3>Conclusions</h3><div>Hepatic Hic-5 expression is associated with advanced liver fibrosis and MASH. Anti-<em>Hic-5</em> ASOs are promising therapeutic interventions for MASH accompanied by advanced fibrosis. These findings provide valuable insights into potential clinical treatments for advanced liver fibrosis.</div></div><div><h3>Impact and implications:</h3><div>This study investigated the role of Hic-5 in liver fibrosis and steatohepatitis, highlighting its potential as a therapeutic target. We developed an antisense oligonucleotide (ASO) that was particularly transportable to the liver, and targeted Hic-5. Anti-<em>Hic-5</em> ASO exhibited therapeutic efficacy for liver fibrosis and steatosis <em>in vivo</em>, indicating its therapeutic potential for liver fibrosis and steatosis. ASOs have already achieved dramatic therapeutic effects as approved nucleic acid drugs. Thus, anti-<em>Hic-5</em> ASO is expected to lead the direct generation of seed compounds for the clinical development of drugs for liver fibrosis and steatosis.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 11","pages":"Article 101195"},"PeriodicalIF":9.5,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the complex macrophage landscape in MASLD","authors":"Federico F. De Ponti ,&nbsp;Zhuangzhuang Liu ,&nbsp;Charlotte L. Scott","doi":"10.1016/j.jhepr.2024.101196","DOIUrl":"10.1016/j.jhepr.2024.101196","url":null,"abstract":"<div><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a spectrum of disease states ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), which can eventually lead to the development of cirrhosis and hepatocellular carcinoma. Macrophages have long been implicated in driving the progression from steatosis to end-stage disease, yet we still know relatively little about the precise involvement of these cells in MASLD progression and/or regression. Rather, there are a considerable number of conflicting reports regarding the precise roles of these cells. This confusion stems from the fact that, until recently, macrophages in the liver were considered a homogenous population. However, thanks to recent technological advances including multi-parameter flow cytometry, single-cell RNA sequencing and spatial proteogenomics, we now know that this is not the case. Rather hepatic macrophages, even in the healthy liver, are heterogenous, existing in multiple subsets with distinct transcriptional profiles and hence likely functions. This heterogeneity is even more prominent in MASLD, where the macrophage pool consists of multiple different subsets of resident and recruited cells. To probe the unique functions of these cells and determine if targeting macrophages may be a viable therapeutic strategy in MASLD, we first need to unravel this complexity and decipher which populations and/or activation states are present and what functions each of these may play in driving MASLD progression. In this review, we summarise recent advances in the field, highlighting what is currently known about the hepatic macrophage landscape in MASLD and the questions that remain to be tackled.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 11","pages":"Article 101196"},"PeriodicalIF":9.5,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142539610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study","authors":"Jean-Charles Nault ,&nbsp;Nanthara Sritharan ,&nbsp;Gontran Verset ,&nbsp;Ivan Borbath ,&nbsp;Marie Lequoy ,&nbsp;Manon Allaire ,&nbsp;Hélène Regnault ,&nbsp;Isabelle Colle ,&nbsp;Hans Orlent ,&nbsp;Isabelle Sinapi ,&nbsp;Christophe Moreno ,&nbsp;Edouard Larrey ,&nbsp;Sabrina Sidali ,&nbsp;Clémence Hollande ,&nbsp;Giuliana Amaddeo ,&nbsp;Stanislas Pol ,&nbsp;Pierre Nahon ,&nbsp;Nathalie Ganne-Carrié ,&nbsp;Vincent Levy ,&nbsp;Coralie Bloch-Queyrat ,&nbsp;Mohammed Bouattour","doi":"10.1016/j.jhepr.2024.101192","DOIUrl":"10.1016/j.jhepr.2024.101192","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>We aimed to explore patient expectations regarding their treatments and prognosis in comparison to physicians' assessments in patients with advanced hepatocellular carcinoma (HCC) receiving systemic treatments.</div></div><div><h3>Methods</h3><div>We prospectively enrolled 205 patients in France and Belgium with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC receiving systemic treatment (NCT04823754). Patients completed a 28-question survey and the hospital anxiety and depression scale (HADS), while physicians filled a 17-question survey after the initial consultation. Univariate and multivariate models were used to assess factors associated with concordant patient-physician responses, HADS, as well as predicted (by physicians) and observed overall survival.</div></div><div><h3>Results</h3><div>Patients had a median age of 68 years with 75% having BCLC C HCC; 86.3% received atezolizumab/bevacizumab. 60% of patients did not discuss life expectancy with the physician. 63% of the patients believed they had a life expectancy &gt;5 years. Among shared questions between patients and physicians, 36.4% concordance was observed; major differences centered on life expectancy with patients more optimistic than physicians. A lower patient-physician concordance was seen with shorter-consultations (<em>p =</em> 0.003), female physicians (<em>p =</em> 0.02), BCLC C (<em>p =</em> 0.03) and &gt;100 HCC patients/year per physician (<em>p =</em> 0.008). Compared to France, patients from Belgium were more likely to be satisfied with the consultation (<em>p</em> &lt;0.001) but were less optimistic about life expectancy. Using HADS, 52% of the patients had anxiety/depression that was correlated with alpha-fetoprotein level (<em>p =</em> 0.03). The predicted median overall survival by physicians was 18 months <em>vs</em>. 13 months for the observed overall survival (weak correlation, ρ = 0.31).</div></div><div><h3>Conclusion</h3><div>Expectations regarding systemic treatments for advanced HCC differ significantly between patients and physicians, showing notable variations across countries.</div></div><div><h3>Impact and implications:</h3><div>This multicentric prospective study, conducted in France and Belgium, focuses on patients with advanced hepatocellular carcinoma undergoing systemic treatments. The findings of our study underscore the disparities in expectations regarding systemic treatments for advanced hepatocellular carcinoma between patients and physicians, revealing also significant variations between France and Belgium. These results suggest the need for targeted interventions aimed at enhancing patients' comprehension of their disease and fostering better communication between patients and physicians.</div></div><div><h3>Clinical trial number</h3><div>NCT04823754.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 11","pages":"Article 101192"},"PeriodicalIF":9.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142427462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study","authors":"Valeria Perez-Campuzano ,&nbsp;Pierre-Emmanuel Rautou ,&nbsp;Thomas Marjot ,&nbsp;Michael Praktiknjo ,&nbsp;Edilmar Alvarado-Tapias ,&nbsp;Laura Turco ,&nbsp;Luis Ibáñez-Samaniego ,&nbsp;Carlos González-Alayón ,&nbsp;Ángela Puente ,&nbsp;Elba Llop ,&nbsp;Macarena Simón-Talero ,&nbsp;Carmen Álvarez-Navascués ,&nbsp;Thomas Reiberger ,&nbsp;Xavier Verhelst ,&nbsp;Luis Tellez ,&nbsp;Johanna Birte Bergmann ,&nbsp;Lara Orts ,&nbsp;Giuseppe Grassi ,&nbsp;Anna Baiges ,&nbsp;Payance Audrey ,&nbsp;Virginia Hernández-Gea","doi":"10.1016/j.jhepr.2024.101191","DOIUrl":"10.1016/j.jhepr.2024.101191","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients with VLD has not been described and represents the aim of our study.</div></div><div><h3>Methods</h3><div>International, multicenter, prospective observational study in patients with VLD analyzing the incidence of COVID-19 infection after vaccination, severity of side effects, occurrence of thromboembolic events and hepatic decompensation. In a subgroup of patients, the humoral and cellular responses to vaccination were also analyzed.</div></div><div><h3>Results</h3><div>A total of 898 patients from 14 European centers – part of the VALDIG network – were included, 872 (97.1%) patients received two vaccine doses (fully vaccinated), and 674 (75.1%) three doses. Of the total cohort, 151/898 had a COVID-19 infection prior to vaccination, of whom 9/151 (5.9%) were re-infected. Of the 747/898 patients who were not previously infected, 11.2% (84/747) were diagnosed with a COVID-19 infection during the study period. Two infected patients required intensive care unit admission and infection was fatal in two fully vaccinated patients. Adverse effects were reported in around 40% of patients, with local side effects being the most frequent. During the study period, 31 (3.5%) patients had thromboembolic events and 21 (2.3%) hepatic decompensations. No cases of vaccine-induced thrombocytopenia were reported. Vaccine immunogenicity was assessed in 36 patients; seroconversion reached 100% and IFNy T-cell responses significantly increased post two mRNA-1273 vaccine doses.</div></div><div><h3>Conclusion</h3><div>Patients with VLD seem to have a preserved immune response to SARS-CoV-2 vaccination, which appears to be safe and effective in preventing severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, though the contribution of vaccination as a cofactor in VLD remains to be elucidated.</div></div><div><h3>Impact and implications:</h3><div>Patients with vascular liver disease (VLD) are at increased risk of both SARS-CoV-2 infection and severe COVID-19 disease. The potential risks associated with vaccination against this infection need thorough investigation. Our research enhances the understanding of the effects of COVID-19 vaccination in patients with VLD, highlighting its good tolerability. Moreover, patients with VLD appear to have a preserved immune response to SARS-CoV-2 vaccination, providing protection against severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, and no cases of vaccine-induced thrombocytopenia were reported.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 12","pages":"Article 101191"},"PeriodicalIF":9.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142657240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD","authors":"Jesse Pustjens ,&nbsp;Laurens A. van Kleef ,&nbsp;Harry L.A. Janssen ,&nbsp;Robert J. de Knegt ,&nbsp;Willem P. Brouwer","doi":"10.1016/j.jhepr.2024.101193","DOIUrl":"10.1016/j.jhepr.2024.101193","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming increasingly prevalent in the general population. This study aimed at describing the cardiometabolic burden of the MASLD population and to identify patients at the highest risk of all-cause mortality and liver fibrosis.</div></div><div><h3>Methods</h3><div>We analysed individuals with MASLD enrolled in the National Health and Nutrition Survey (NHANES) III study (N = 3,628) and in the NHANES 2017–2020 study (n = 2,618). MASLD was defined as hepatic steatosis (by ultrasonography or controlled attenuation parameter), together with cardiometabolic dysfunction. Primary endpoints were all-cause mortality and liver fibrosis (liver stiffness measurement ≥8 kPa). Regression models were adjusted for age, sex, race, marital status, education, and smoking, and results were stratified by age groups (20–40, 40–60, 60–80 years).</div></div><div><h3>Results</h3><div>Among the total MASLD population (median age = 48, [25th to 75th percentiles: 36–62] years, 44.8% males), 65% had three or more cardiometabolic disorders. The most frequent were obesity (89.1%), (pre-) diabetes (66.6%), and low-HDL (54.7%). During a median follow-up of 22.3 (25th to 75th percentiles: 16.9–24.2) years, 1,405 deaths occurred. Hypertension (adjusted hazard ratio [aHR] 1.42, 95% CI 1.26–1.61), (pre-)diabetes (aHR 1.28, 95% CI 1.09–1.49), and hypertriglyceridaemia (aHR 1.19, 95% CI 1.05–1.34) were the strongest predictors of all-cause mortality. Consistent results were obtained regarding the association between cardiometabolic disorders and fibrosis. Here, increased waist circumference (adjusted odds ratio [aOR] 3.45, 95% CI 1.44–8.25), (pre-)diabetes (aOR 1.90, 95% CI 1.44–2.25), and hypertension (aHR 1.84, 95% CI 1.40–2.43) showed the strongest associations.</div></div><div><h3>Conclusions</h3><div>MASLD patients vary greatly in their cardiometabolic burden and consequently, in their prognosis. Our results highlight MASLD as a disease spectrum rather than as a single disease entity, necessitating an individualised treatment approach.</div></div><div><h3>Impact and implications:</h3><div>The increasing cardiometabolic burden and incidence of MASLD, especially among younger adults, stresses the importance of the current study.² Understanding the disease burden of MASLD patients is key, but can be challenging for healthcare professionals. Results from the current study indicate that cardiometabolic risk management is particularly warranted in the younger adult population, with specific attention to hypertension and (pre-)diabetes.</div></div>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":"6 12","pages":"Article 101193"},"PeriodicalIF":9.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}